Advanced
Interaction of CFP with Metal ions: Complex Formation of CFP with Metal ion by Absorption and Fluorescence Spectrophotometery
Interaction of CFP with Metal ions: Complex Formation of CFP with Metal ion by Absorption and Fluorescence Spectrophotometery
Journal of the Korean Chemical Society. 2009. Apr, 53(2): 152-158
Copyright © 2009, The Korean Chemical Society
  • Received : December 24, 2008
  • Published : April 20, 2009
Download
PDF
e-PUB
PubReader
PPT
Export by style
Article
Author
Metrics
Cited by
TagCloud
About the Authors
K. S. Siddiqi
Ayaz Mohd
Aftab Aslam Parwaz Khan
Shaista Bano

Abstract
Spectrophotometric investigation of the interaction of Cefpodoxime proxetil (CFP) with Ca 2+ , Mg 2+ , Mn 2+ , Fe 3+ , Co 2+ , Ni 2+ , Cu 2+ and Zn 2+ in acidic medium showed the formation of 1:1 complex. The absorption spectrum of pure drug exhibits two prominent peaks at 270 and 345 nm. Its spectra scanned at several pH exhibited two isosbestic points (305 and 330 nm) indicating the presence of zwitterionic condition of drug in solution phase. The fluorescence emission spectra of CFP in presence of different concentrations of metal ions showed enhancement in fluorescence intensity which is ascribed to chelating enhancement fluorescence effect (CHEF). The stoichiometry of the complexes was determined by Job’s and Benesi-Hildebrand method. The stability of the complexes follow the order Ca 2+ < Mg 2+ < Co 2+ < Ni 2+ < Zn 2+ < Mn 2+ < Cu 2+ < Fe 3+ .
Keywords
INTRODUCTION
Cefpodoxime proxetil (CFP) is a semisynthetic β-lactum antibiotic known as (RS)-1(isopropoxycarbonyloxy) ethyl (+)-(6R, 7R)-7-[2-(2-amino-4-thiazolyl)-2-{(Z) methoxyimino} acetamido]-3-methoxymethyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate. It is an ester prodrug of cefpodoxime acid where a proxetil radical is attached to cefpodoxime acid ( . 1 ). It is the third generation cephalosporin ester, used in the treatment of upper respiratory tract and urinary tract infection. In biological system cefpodoxime undergoes ester hydrolysis and converted into cefpodoxime acid to exhibit its antibiotic activity. 1 , 2 It has an asymmetric carbon at position 4 and is supplied as racemic mixture of R and S-enantiomers. Only a few methods are reported to quantify CFP, 3 , 4 nevertheless the analytical methods of detection of CFP are handful, and they employ RPHPLC. These methods are based on separation of the R- and S-isomers. 5 However, both the isomers are reported to exhibit similar biological activity, 1 the use of highly sophisticated and time-consuming methods is not always required for routine analysis of CFP from the different dosage forms.
PPT Slide
Lager Image
Structure Cefpodoxime Proxetil (CFP).
The discovery of cephalosporin from C.acremonium culture by Brotzu 6 and demonstration of its remarkable stability towards aqueous solution even at pH 2 as well as its excellent in vitro activity against penicillin-resistant organisms by Abraham and Newton, 7 were major breakthroughs in the history of β-lactam antibiotics. The realization that fungi might be a good source for novel antibiotics spurred microbiologists to develop novel soilscreening programmes for the investigation of microbial culture leading to the discovery of several non-classical β-lactams like carbapenem 8 and oxacephems. 9 The reactivity of β-lactam antibiotics is fundamentally linked to antimicrobial activity, it led Woodward 10 to design and synthesize carbapenem group of compounds for evaluation of their antibacterial activity through systematic screening of the soil microorganism. Numerous of these compounds show broad-spectrum antimicrobial activity as predicted earlier and it was further substantiated by the subsequent discovery of thienamycin. It is unstable in its pure form and hence its derivatives are used which also led to the introduction of imipenem, which is regarded as one of the most effective drugs among the β-lactam antibiotics. Although several methods have been developed to determine the drug in biological fluids and pharmaceutical preparations 11 no effort seems to have been made to investigate the interaction of the drug with metal ions.
Stability constant and other thermodynamic parameters of CFP complexes (Job's method)
PPT Slide
Lager Image
Stability constant and other thermodynamic parameters of CFP complexes (Job's method)
In the present work an earnest effort has been made to study the interaction of the CFP with metal ions by fluorescence emission and absorption spectrophotometric measurements. Since quenching or enhancement in fluorescence intensity of the drug in presence of metal ions occurs, the spectra of the drug in presence of different concentrations of metal ions such as Ca 2+ , Mg 2+ , Mn 2+ , Fe 3+ , Co 2+ , Ni 2+ , Cu 2+ , and Zn 2+ were scanned. The ratio of the drug to metal ions was determined by Job’s method and Benesi-Hildebrand methods. 12 , 13 The absorption spectra of the drug in the pH range 2.32-11.50 were run to see the zwitterionic condition, apparent ionization constant and the isosbestic point which indicate the presence of different species in solution. The stability constant of the complexes formed between the drug and metal ion was also evaluated.
Stability constant, Gibbs energy change of CFP complexes (Benesi‐Hildebrand method) at 25 ℃
PPT Slide
Lager Image
Stability constant, Gibbs energy change of CFP complexes (Benesi‐Hildebrand method) at 25 ℃
EXPERIMENTAL
- Instruments
The absorption spectra were obtained with Elico-SL-169 double beam UV-visible spectrophotometer. Fluorescence emission spectra were scanned with Hitachi-F-2500FL-spetrophotometer. All potentiometric measurements were done with Elico-LI-120 pH meter.
- Methods and materials
Double distilled water was used throughout Cefpodoxime proxetil (Lupin pharmaceutical Ltd, India), sodium hydroxide and metal chloride (Merck Ltd, Mumbai, India) and HCl (Ranbaxy fine chem. Ltd, India) were used as received.
- Preparation of solution
Stock solution of Cefpodoxime proxetil and metal salts of 1×10 -3 M were prepared in 1×10 -2 M HCl. Stock solution of drug was stored at 4 ℃.
- Spectrophotometric method
Solutions of equimolar concentration (1×10 -4 M) of CFP and metal ions were prepared. The pH of the drug was adjusted between 2.32 to 11.50 by adding sodium hydroxide and hydrochloric acid (1×10 -1 M and1×10 -2 M respectively). The absorption spectra were recorded in the range 250-380 nm. The ratio of metal to CFP was determined by Job’s method. The linearity of CFP was found in the range 2×10 -5 to 6×10 -4 mg/ml and the correlation factor (R 2 ) 0.9236.
- Fluorescence study
Solution of the CFP (7×10 -6 M) and those of metal ions (1×10 -6 to 7×10 -6 M) were prepared. To prepare dilute solutions, an aliquot of stock solution was placed in a 10 ml volumetric flask and made up to the mark with distilled water. Spectra were recorded immediately after sample preparation in the optimum wavelength range 370-430 nm at optimum excitation wavelength of 335 nm. For calibration curve an aliquot of stock solution (1×10 -6 to 3×10 -5 mg/ml) was prepared which showed linearity with correlation factor (R 2 ) 0.9652
RESULTS AND DISCUSSION
- Spectrophotometric study
The absorption spectrum of CFP (1×10 -4 M) was run in the region 250-380 nm. It exhibited two peaks at 270 and 345 nm ( . 2 ). Since the first peak is very strong it was selected for further absorption studies.
When the spectra of the drug were run at varying pH in the region 250-380 nm two isosbestic points, one at 305 nm and another at 330 nm were observed which indicated the presence of zwitter ionic condition in solution ( . 3 ). 14 The apparent ionization constant (pKa') of the drug was calculated (8.92) by the following equation.
PPT Slide
Lager Image
Absorption spectrum of CFP (1×10‐4 M) at pH 5.15.
PPT Slide
Lager Image
Absorption Spectra of CFP (1×10‐4 M) in (2.32‐ 11.50) pH range.
PPT Slide
Lager Image
where, A I = absorbance of drug in basic medium, A M = absorbance of drug in acidic medium, A= absorbance of drug in aqueous medium.
The absorption spectra corresponding to the metal, drug and complexes were obtained in acidic medium. The concentration of cations and drug (CFP) were 1×10 -4 M. The stoichiometry of the complexes was obtained by Job’s methods 12 , 15 a sample of resulting plots is shown in . 4 . The stability constant of chelate formed is calculated by following equation
PPT Slide
Lager Image
where, K is the stability constant of the metal chelate formed in the solution, M = metal, L = ligand, X = mole fraction of the ligand at maximum absorption. A/A ex is the ratio of the absorbance to that indicated by the tangent for the same wavelength. C x , C M and C L are the limiting concentration of complex, metal ion and the drug respectively.
The stability constant is related to the standard enthalpy changes ΔH and other thermodynamic function by the equation:
PPT Slide
Lager Image
where R is the gas constant T is the experimental temperature, K is the binding constant at the corresponding temperature.
PPT Slide
Lager Image
Continuous variation curves of CFP and metal complexes.
From the value of stability constant at different temperature the enthalpy changes can be calculated by using the equation:
PPT Slide
Lager Image
The negative value of ΔG for the complexation process suggests spontaneous nature of such process. 16 , 17 The positive value of ΔH suggests that these processes are endothermic and are favourable at higher temperature. Also it is entropically favourable. The positive value of H and S indicates that hydrophobic force may play a major role in the interaction. 18 It is reasonable to think, on the basis of these results that the metal ions form a five membered chelate ring with CFP.
PPT Slide
Lager Image
Mechanism of binding of CFP with metal ions: A. CFP, B. CFP‐metal complex, C hydrolyzed form of complex.
- Fluorescence study
The fluorescence emission spectrum of the pure drug is markedly different from its absorption spectrum in UV region. The emission spectrum run between 350-450 nm at excitation wavelength of 335 nm showed a peak at 400 nm. The addition of metal ions to the drug causes enhancement or quenching in the fluorescence spectrum. We have noted an enhancement in fluorescence intensity at 400 nm in each case (Ca 2+ , Mg 2+ , Mn 2+ , Fe 3+ , Co 2+ , Ni 2+ , Cu 2+ and Zn 2+ ) ( . 6 ) although the shape and position of emission spectrum remains unchanged.
The stoichiometry and stability constant of the complexes was determined by Benesi-Hildbrand method. 13 The Benesi-Hildebrand plots were examine to further characterize the stoichiometry of the CFP-metal complexes. In case of a 1:1 complex, the following equation is applicable:
PPT Slide
Lager Image
Fluorescence enhancement (at λex 335nm) of CFP in presence of metal ions.
PPT Slide
Lager Image
In this approach, a graph of 1/(F − F o ) versus 1/[Me] o , was made where F is the observed fluorescence at each concentration tested, F o is the fluorescence intensity of analyte in the absence of metal ion, F is the maximum fluorescence intensity in presence of metal ions and [Me] o is the concentration of metal ion. A linear plot is required for this double reciprocal plot in order to conclude 1:1 stoichiometry. In such cases, a linear relationship has to be obtained when 1/(F − F o ) versus 1/[Me] o is plotted. The stability constant is determined by dividing the intercept by the slope of the straight line obtained in the double-reciprocal plot. ( . 7 )
PPT Slide
Lager Image
Benesi-Hildebrand's plots for 1:1 (CFP: metal complexes)
- Influence of metal ion concentrations
The influence of metal ions concentration was studied in the range of 1×10 -6 -10×10 -6 M. The fluorescence study of interaction CFP with metal ions in acidic aqueous medium showed 1:1 stoichiometry. Both these study also support the formation of 1:1 CFP:Metal complex, with the possibility of metal ions chelating with CFP by β-actum carbonyl carbon and acidamide nitrogen.
In general, the phenomenon of enhancement is observed because the complexation by cations causes increase in the redox potential of the donor so that the relevant HOMO energy decreases to a level lower than that of fluorophore. Consequently the excited state energy of fluorophore is dumped as a visible emission. 19
The reason of this enhancement lies in strong perturbation of the excited state upon coordination of the metal ion. A low lying internal charge transfer state due to the presence of electron donor and acceptor group in the CFP is the lowest excited state, this state is however, a less emitting state and in equilibrium with the π-π * excited state of the molecule, upon coordination with metal cation the PCT interaction becomes weaker since the electron withdrawing group is now electron rich moiety due to the deprotonation of –NH group necessary for coordination of metal cation.
In the present work an attempt has been made to study the interaction of the CFP with metal ions by fluorescence emission, absorption spectrophotometric and measurements. Since enhancement in fluorescence intensity of the CFP in presence of the metal ions occurs, the spectra of the drug in presence of different concentrations of several metal ions were scanned. The ratio of the drug to metal ions was determined by Job’s and Benesi-Hildbrand method. The absorption spectra of the CFP was run at different pH to see the zwitterionic condition, apparent ionization constant and the isosbestic point indicating the presence of different species in solution. The stability constant of the complex formed between the drug and metal ion was also evaluated.
CONCLUSION
In this paper the nature and magnitude of the interaction of CFP with biologically important metal ion was investigated by fluorescence spectra and UV spectra. The experimental result indicated the formation of 1:1 complex of CFP with metal ions in acidic medium by Job’s and Benesi-Hildbrand method. The absorption spectra at different pH showed the presence of two isosbestic point indicating the existence of zwitterionic condition. The thermodynamic parameters showed that the interaction between CFP and metal ion was spontaneous, and that the hydrophobic force was a major factor in the interaction.
References
Borin M. T. 1991 Drugs 42 13 -    DOI : 10.2165/00003495-199100423-00005
Rodrıguez J. C. , Hernandez R. , Gonzalez M. , Rodrıguez Z. , Tolon B , Velez H. , Valdes B. , Lopez M. A. , Fini A. 2003 II Farmaco. 58 363 -    DOI : 10.1016/S0014-827X(03)00051-X
Camus F. , Deslandes A. , Harcouet L. , Farinotti R. 1994 J. Chromatogr B. 656 383 -    DOI : 10.1016/0378-4347(94)00122-7
Steenwyk R. C. , Brewer J. E. , Royer M. E. , Cathcart K. S. 1991 J. Liq. Chromatogr. 14 3641 -    DOI : 10.1080/01483919108049483
Fakutsu N. , Kawasaki T. , Saito K. , Nakazawa H. 2006 J. Chromatogr. A. 1129 153 -    DOI : 10.1016/j.chroma.2006.06.102
Abraham E. P. 1987 Drugs 34 1 -    DOI : 10.2165/00003495-198700342-00003
Abraham E. F , Newton G. G. H. 1961 Biochem. J. 79 377 -
Nagahara T. , Kametani T. 1987 Heterocycles 25 729 -    DOI : 10.3987/S-1987-01-0729
Nagata W. 1989 Pure Appl. Chem. 61 325 -    DOI : 10.1351/pac198961030325
Mitsuhashi S. , Franseschi G. 1991 Penem Antibiotics Japan Scientific Societies Press: Springer Verlag Berlin 26 -
Antonio L. , Doadrio A. M. , Regina O. 2002 J. Braz. Chem. Soc. 13 95 -    DOI : 10.1590/S0103-50532002000100015
Job P. 1928 Ann. Chim. Phys. 9 113 -
Benesi H. , Hildebrand J. H. 1949 J. Am. Chem. Soc. 71 2703 -    DOI : 10.1021/ja01176a030
Park H. R. , Chung K. Y. , Lee H. C. , Lee J. K. , Bark K. M. 2000 Bull. Chem. Soc. 21 849 -
Vosburgh W. C. , Copper G. R. 1941 J. Am. Chem. Soc. 63 437 -    DOI : 10.1021/ja01847a025
El-Sonbati A. Z. , El-Bindary A. A. , Ahmad R. M. 2003 J. Solution Chem. 32 617 -    DOI : 10.1023/A:1026392306114
Bebot-Brigaud A. , Dange C. , Fauconnier N. , Gérard C. 1999 J. Inorg. Biochem. 75 71 -    DOI : 10.1016/S0162-0134(99)00041-0
Ross P. D. , Subramanium S. 1981 Biochemistry 20 3096 -    DOI : 10.1021/bi00514a017
Quang D. T. , Jung H. S. , Yoon J. H. , Lee S. Y. , Kim J. S. 2007 J. Bull. Korean Chem. 28 682 -    DOI : 10.5012/bkcs.2007.28.4.682